References
- GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. [cited 2017 May 9]. Available from: http://globocan.iarc.fr/Default.aspx.
- Podolsky DK, Camilleri M, Fitz JG, et al. editors. Yamada's textbook of gastroenterology. 6th ed. London (UK): Wiley; 2015.
- Schreuders EH, Ruco A, Rabeneck L, et al. Colorectal cancer screening: a global overview of existing programmes. Gut. 2015;64:1637–1649.
- Sundhetsstyrelsen (Denmark). Pakkeforløb for kraeft i tyk-og endetarm (Cancer pathways. National integrated cancer pathway for colorectal cancer). Copenhagen: 2016. [cited 2017 May 9]. Available from: http://sundhedsstyrelsen.dk/da/sygdom-og-behandling/kraeft/pakkeforloeb/beskrivelser.
- Högberg C, Samuelsson E, Lilja M, et al. Could it be colorectal cancer? General practitioners' use of the faecal occult blood test and decision making – a qualitative study. BMC Fam Pract. 2015;16:153.
- Allison JE, Fraser CG, Halloran SP, et al. Population screening for colorectal cancer means getting FIT: the past, present, and future of colorectal cancer screening using the fecal immunochemical test for hemoglobin (FIT). Gut Liver. 2014;8:117–130.
- Högberg C, Karling P, Rutegård J, et al. Diagnosing colorectal cancer and inflammatory bowel disease in primary care: the usefulness of tests for faecal haemoglobin, faecal calprotectin, anaemia, and iron deficiency. A prospective study. Scand J Gastroenterol. 2017;52:69–75.
- Cubiella J, Salve M, Diaz-Ondina M, et al. Diagnostic accuracy of the faecal immunochemical test for colorectal cancer in symptomatic patients: comparison with NICE and SIGN referral criteria. Colorectal Dis. 2014;16:O273–O282.
- Rodriguez-Alonso L, Rodriguez-Moranta F, Ruiz-Cerulla A, et al. An urgent referral strategy for symptomatic patients with suspected colorectal cancer based on a quantitative immunochemical faecal occult blood test. Dig Liver Dis. 2015;47:797–804.
- Park DI, Ryu S, Kim YH, et al. Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening. Am J Gastroenterol. 2010;105:2017–2025.
- Raginel T, Puvinel J, Ferrand O, et al. A population-based comparison of immunochemical fecal occult blood tests for colorectal cancer screening. Gastroenterology. 2013;144:918–925.
- Wu D, Luo HQ, Zhou WX, et al. The performance of three-sample qualitative immunochemical fecal test to detect colorectal adenoma and cancer in gastrointestinal outpatients: an observational study. PLoS One. 2014;9:e106648.
- Kapidzic A, van Roon AH, van Leerdam ME, et al. Attendance and diagnostic yield of repeated two-sample faecal immunochemical test screening for colorectal cancer. Gut. 2017;66:118–123.
- Högberg C, Karling P, Rutegård J, et al. Immunochemical faecal occult blood tests in primary care and the risk of delay in the diagnosis of colorectal cancer. Scand J Prim Health Care. 2013;31:209–214.
- Publication Office of the European Union. European guidelines for quality assurance in colorectal cancer screening and diagnosis. Luxembourg (Europe): Publication Office of the European Union; [Internet]. 2011. Available from: http://bookshop.europa.eu.
- Oy Medix Biochemica Ab (Finland). Espoo: 2016. [cited 2017 May 9]. Available from: http://www.medixbiochemica.com.
- Brown LD, Cai TT, DasGupta A. Interval estimation for a binomial proportion. Statist Sci. 2001;16:101–133.
- Auge JM, Fraser CG, Rodriguez C, et al. Clinical utility of one versus two faecal immunochemical test samples in the detection of advanced colorectal neoplasia in symptomatic patients. Clin Chem Lab Med. 2016;54:125–132.
- Mowat C, Digby J, Strachan JA, et al. Faecal haemoglobin and faecal calprotectin as indicators of bowel disease in patients presenting to primary care with bowel symptoms. Gut. 2016;65:1463–1469.